Results 31 to 40 of about 1,033,768 (122)
The Journal of Headache and Pain, 2021 Background Calcitonin gene-related peptide (CGRP) (receptor) antibodies (erenumab, fremanezumab and galcanezumab) are increasingly used in prophylactic treatment of migraine.
Armin Scheffler +6 more
doaj +1 more source
Associations between stress and migraine and tension-type headache: Results from a school-based study in adolescents from grammar schools in Germany [PDF]
, 2011 Introduction: Stress is considered the major contributor to migraine and tension-type headache in adolescents. Previous studies have focused on general stressors, whereas the aim of the present study was to investigate associations between individuals ...
Straube, Andreas +15 more
core +1 more source
Headache Medicine, 2020 Introduction Acute headache medication use (AHM) and health care resource utilization (HCRU) in patients with protocol-defined treatment-resistant migraine treated with galcanezumab (GMB).
Anna Ambrosini +6 more
doaj +1 more source
Brain and Behavior, 2022 Background Current German and European guidelines suggest migraine patients undertake a treatment break after 9 to 12 months of treatment with CGRP (pathway) monoclonal antibodies.
Michael Nsaka +6 more
doaj +1 more source
Botulinum Toxin as Preventive Treatment for Migraine: A Randomized Double-Blind Study [PDF]
, 2009 Aim: To determine if botulinum toxin type A (BoNT-A) injections can reduce the frequency and severity of migraines. Methods: Patients (n = 127) were randomized to receive placebo or two doses of BoNT-A (Dysport (R)). The primary endpoint was reduction in
Toelle, Thomas +13 more
core +1 more source
Self-reported muscle pain in adolescents with migraine and tension-type headache [PDF]
, 2012 Aim: To identify possible associations between muscular pain and headache in adolescents in a large population-based sample. Methods: Grammar school students were invited to fill in a questionnaire on headache and associated lifestyle factors.
Straube, Andreas +9 more
core +1 more source
Revisiting the expanded use of hyperbaric oxygen therapy for treatment of resistant migraines [PDF]
Medical Gas Research, 2019 There are currently 13 indications approved by the U.S. Food and Drug Administration for use of hyperbaric oxygen therapy. The European Consensus Conference on Hyperbaric Medicine has 28 indications approved for its use. However, neither includes the use of hyperbaric oxygen therapy for neurological conditions such as migraines with aura.
Matera, David V +2 more
openaire +2 more sources
P/Q-type calcium-channel blockade in the periaqueductal gray facilitates trigeminal nociception: a functional genetic link for migraine? [PDF]
, 2002 The discovery of mis-sense mutations in the alpha1A subunit of the P/Q-type calcium channel in patients with familial hemiplegic migraine indicates the potential involvement of dysfunctional ion channels in migraine.
Goadsby, PJ +11 more
core +1 more source
Association of patent foramen ovale with epilepsy: A hospital‐based case–control study
Epilepsia Open, 2023 Objective This study aimed to investigate the proportion of patent foramen ovale (PFO) in people with epilepsy (PWE) compared to controls without epilepsy and to assess whether PWEs with and without PFO exhibit distinctive clinical features. Methods This
Yusha Tang +6 more
doaj +1 more source
The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions
Pharmaceuticals, 2021 Galcanezumab is a humanized monoclonal antibody blocking the calcitonin gene-related peptide (CGRP) pathway by targeting the CGRP. Data from four phase-3 randomized placebo-controlled clinical trials showed that galcanezumab is superior to placebo in ...
Panagiotis Gklinos, Dimos D. Mitsikostas
doaj +1 more source